AstraZeneca has entered an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a ‘satellite unit’ in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.
The new collaboration will see AstraZeneca scientists working side-by-side with researchers from the Max Planck Institute of Molecular Physiology, in the Department of Chemical Biology, led by Professor Herbert Waldmann. The satellite unit will focus on novel chemistry and chemical biology in areas of new modality chemistry such as stabilized peptides, macrocycles and conjugation chemistry.
Marcus Schindler, Vice President and Head of CVMD iMed, AstraZeneca, said, “I’m very pleased to collaborate with an internationally recognized academic institution such as the Max Planck Institute of Molecular Physiology. Based on our excellent ongoing collaboration with Professor Waldmann’s group and the interdisciplinary Chemical Genomics Centre, we are confident that this innovative new partnership will result in exciting scientific findings, addressing chemical challenges primarily in the field of new modalities.”
Professor Herbert Waldmann, Director of the Department of Chemical Biology, MPI Dortmund, said, “This novel concept for a strategic alliance between an innovation-driven pharmaceutical company and a leading biomedical institute like the Max Planck Institute of Molecular Physiology promises to break new ground for drug discovery. AstraZeneca is one of the leading global pharmaceutical companies and we are pleased and very much looking forward to the collaboration. Uniting our strengths will give rise to novel innovative approaches to drug discovery.”
Click here for the complete issue.